roove Biosciences, an Irvine, Calif., genetic-testing company, describes itself as “the leader in personalized pain medicine.” It’s received a bunch of fawning media coverage for its claims that its tests might help combat the national opioid crisis.

My article last December showed, however, that top experts in the field regard the firm’s claims to be able to predict with great accuracy which patients will become dependent on opioids as scientifically unsupported “hogwash.”

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for our
Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine — delivered straight to your inbox every weekday afternoon.

Recommended Stories